Strategic Portfolio Prioritization in the Age of Gene and Cell Therapy
White Paper|
By Sarah Jims, Kelly Drews, Matthew Haynes, Neela Mahanty, Grant Petersen, Vaibhav Shrishail
As the possibilities of gene and cell therapy move from breakthroughs in the lab to commercial realities, biotechnology and pharmaceutical companies are tasked with identifying the next set of opportunities to grow their portfolio.
Strategic Portfolio Prioritization in the Age of Gene and Cell Therapy
Please submit the form below to view this resource.